Core Viewpoint - President Trump claimed that the U.S. government has reduced prescription drug prices by up to 1500%, a statement that has been widely criticized by media outlets as mathematically impossible [1][3]. Group 1: Drug Pricing Claims - Trump stated that drug prices have been lowered by 1200%, 1300%, 1400%, and 1500%, emphasizing that these figures are not mere percentages like 50% [3]. - Media outlets pointed out that a 100% price reduction would mean drugs are free, while a reduction exceeding 100% implies that pharmaceutical companies would pay consumers to take the drugs [3]. Group 2: Government Response - White House spokesperson Kush DeSantis defended Trump's claims by stating that Americans pay significantly more for the same medications compared to other developed countries, asserting that the Trump administration has made substantial efforts to alleviate this burden [3]. - The statement reflects a misunderstanding of pricing and percentage operations, potentially undermining public confidence in Trump's ability to address drug pricing issues [3]. Group 3: Tariff Threats and Industry Impact - Trump has threatened to impose high tariffs on imported drugs, claiming this would lower drug prices and enhance national security [3]. - Industry professionals argue that achieving these goals is challenging due to complex supply chains and high domestic production costs, with tariff policies introducing further uncertainty for the U.S. pharmaceutical industry and companies [3].

Group 1: Steel Industry - In July, the PMI for new export orders was reported at 47.10% [4] - The BCI for small and medium enterprises financing environment index in July 2025 was 46.09, a month-on-month decrease of 6.16% [4] - The M1 and M2 growth rate difference in June 2025 was -3.7 percentage points, with a month-on-month increase of 1.9 percentage points [4] Group 2: Non-ferrous Metals - In July, the operating rate of cable enterprises reached a six-year low compared to the same period last year [4] - The copper price is expected to fluctuate in the short term due to lower domestic cable operating rates and a decrease in air conditioning production from August to October [4] - However, tight supply from mines and scrap copper, along with a rebound in demand for power grids and air conditioning in Q4, may lead to an increase in copper prices [4] Group 3: Renewable Energy and Environmental Protection - The political bureau meeting emphasized the importance of promoting a unified national market and optimizing market competition [4] - The "anti-involution" policy is expected to continue, impacting the stock prices of photovoltaic-related companies [4] - Key areas to watch include price-sensitive segments such as silicon materials, glass, and BC batteries [4] Group 4: Pharmaceutical and Biotechnology - The public health emergency response level III was activated in Foshan due to the outbreak of Chikungunya fever, with over 6,000 confirmed cases reported by July 31 [5] Group 5: Company-Specific Developments - New An Co., Ltd. has established a new subsidiary focused on synthetic materials, indicating a strengthened global development strategy [6] - China Shenhua announced plans to acquire assets from the State Energy Group, including coal and related energy assets [6] - TAL Education Group reported a revenue of $575 million for FY26Q1, a year-on-year increase of 38.8%, with net profit significantly exceeding expectations [6]

（文章来源：每日经济新闻） 嘉应制药（SZ 002198，收盘价：6.94元）8月4日晚间发布公告称，截至2025年7月31日，公司通过股票 回购专用证券账户以集中竞价方式已累计回购公司股份924万股，占公司目前总股本的1.8206%，回购 的最高成交价格为7.04元/股，最低成交价格为5.96元/股，成交总金额约为6226万元。 2024年1至12月份，嘉应制药的营业收入构成为：医药行业占比99.8%，其他业务占比0.2%。 ...

Macro - The significant downward revision of the U.S. non-farm employment data for June indicates a major impact from tariffs on the U.S. economy, suggesting that the resilience of the economy should not be overestimated, and the direction of interest rate cuts remains clear [5]. Basic Chemicals - The Central Political Bureau emphasized "capacity governance" and "technological innovation," indicating that the domestic chemical industry may benefit from the exit of outdated capacity and the focus on high-performance new materials such as semiconductor materials and OLED materials [5]. Coal Mining - The average price of thermal coal at Qinhuangdao Port increased by 9 CNY/ton (+1.36%) week-on-week, marking six consecutive weeks of price increases. The coal inventory at the port decreased to 5.22 million tons, down 10.77% week-on-week, indicating a tightening supply-demand situation [6][7]. Company Updates - China Merchants Shekou (001979.SZ) has repurchased a total of 44,804,006 shares, accounting for 0.494% of the total share capital, with a total payment of approximately 430.27 million CNY [8]. ARM - ARM's FY26Q1 revenue was $1.053 billion, a year-on-year increase of 12%, but the guidance for FY26Q2 is relatively flat, indicating challenges and opportunities in self-designed chips [8]. Apple - Apple's FY3Q25 results exceeded expectations, showcasing strong resilience due to its core product strength and software ecosystem. However, there is a need for continued focus on AI advancements and tariff pressures [8]. Yunnan Baiyao - Yunnan Baiyao has made significant progress in cost reduction and efficiency enhancement, accelerating the development of innovative nuclear drugs [9].

Investment Rating - The report rates the pharmaceutical industry as "Overweight," indicating an expectation for the industry to outperform the overall market [27]. Core Insights - The pharmaceutical sector saw a weekly increase of 2.9%, outperforming the Shanghai Composite Index, which declined by 0.9% [2][3]. - The overall valuation of the pharmaceutical sector is at 32.6 times PE for 2025E, ranking 6th among 31 primary industries [6][13]. - Significant transactions in the innovative drug sector have been noted, with large business development (BD) deals driving growth expectations [2]. Market Performance - The pharmaceutical and biotechnology index increased by 2.9%, ranking first among 31 sub-industries [3]. - The performance of various sub-sectors includes: - Chemical preparations (+5.5%) - Other biological products (+5.4%) - Traditional Chinese medicine (+3.1%) - Medical devices (-1.4%) [6][11]. Key Events - The sixth batch of high-cost medical supplies procurement was initiated on August 1, focusing on drug-coated balloons and urological intervention products [14]. - The eleventh batch of drug procurement rules was released for public consultation, introducing new bidding mechanisms and price caps [14]. - The State Council approved the "Artificial Intelligence+" action plan, promoting AI applications across various sectors [15]. Major Transactions - Heng Rui Pharmaceuticals entered a $12.5 billion overseas licensing agreement with GSK, with an upfront payment of $500 million and potential milestone payments of up to $12 billion [16]. - Shiyao Group signed a licensing agreement with Madrigal for a GLP-1 drug, with a total potential value of $2.075 billion [16]. Company Performance - WuXi AppTec forecasted a revenue of 20.8 billion yuan for H1 2025, a 20.6% year-on-year increase, and raised its full-year revenue guidance to 42.5-43.5 billion yuan [17].

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index decreased by 0.59% as of July 30, 2025, with mixed performance among constituent stocks [1] - Dongxin Co., Ltd. led the gains with an increase of 18.63%, while Shengyi Electronics fell by 5.66% [1] - The Huaxia Sci-Tech 100 ETF (588800) dropped by 0.56%, with a recent price of 1.07 yuan, but saw a weekly increase of 5.06% as of July 29, 2025 [1] Group 2 - The State Council Information Office recently held a press conference discussing the high-quality completion of the 14th Five-Year Plan, focusing on deepening medical insurance reform [1] - The National Medical Insurance Administration emphasized the principle of "anti-involution" in the 11th batch of centralized procurement, aiming to optimize procurement rules [1] - The impact of centralized procurement on drug prices in the pharmaceutical industry has been significant, but expectations for price stabilization may lead to gradual improvement in profitability [1] Group 3 - Zhongyin Securities noted a shift in policy attitudes towards the pharmaceutical sector, with optimized procurement rules and a recovery phase for R&D pipelines [2] - The trend of overseas business development in the pharmaceutical industry is accelerating, showcasing the global competitiveness of China's innovative drugs [2] - The Huaxia Sci-Tech 100 ETF (588800) closely tracks the Sci-Tech 100 Index, focusing on high-growth sectors such as semiconductors, pharmaceuticals, and new energy [2]

Group 1 - The core viewpoint of the news is the emphasis on the dual role of medical insurance as both a financial support system and a service provider, highlighting its contributions to the healthcare industry and economic development [1][2] - The National Medical Insurance Bureau has established a prepayment system for medical insurance funds and has implemented real-time settlement reforms, covering 357 regions and disbursing 594.8 billion yuan since 2025 [2] - The medical insurance fund has cumulatively spent 12.13 trillion yuan since the beginning of the 14th Five-Year Plan, with an annual growth rate of 9.1%, significantly supporting both patient reimbursements and the pharmaceutical industry [3] Group 2 - The medical insurance system is promoting reforms and openness, including the implementation of centralized drug procurement reforms and the establishment of a new directory for innovative drugs under commercial health insurance [4] - The National Medical Insurance Bureau is actively supporting the development of traditional Chinese medicine while also fostering innovation in medical technologies, such as artificial hearts and brain-machine interfaces [5] - Future initiatives will focus on effectively managing medical insurance funds to enhance the efficiency, safety, and accessibility of medical products and services, contributing to the overall health of the population [5]

最近三个交易日，25日-29日，香港医药(513700)分别获融资买入0.22亿元、0.24亿元、0.36亿元。 7月29日，沪深两融数据显示，香港医药(513700)获融资买入额0.36亿元，居两市第574位，当日融资偿 还额0.39亿元，净卖出228.48万元。 本文源自：金融界 作者：智投君 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 ...

Group 1 - The US and EU have reached a new trade agreement, with the US imposing a 15% tariff on EU products and the EU committing to invest $600 billion and purchase $750 billion worth of US energy [2][4] - The agreement is seen as a compromise, avoiding a potential trade war that could have resulted from a proposed 30% tariff by the US [3][4] - The new tariff rate is significantly higher than the previous average of around 2%, which poses challenges for EU product competitiveness [5][7] Group 2 - Germany, as the largest EU economy, benefits from the agreement as it reduces the average tariff on automotive exports from 27.5% to 15%, thus protecting its key industries [4][6] - The agreement has sparked criticism within the EU, with some leaders arguing it represents a loss for European industries and could threaten jobs [7][8] - The potential for increased US procurement and investment from the EU raises questions about the actual implementation and market willingness to follow through [8]

Core Points - The US and EU have reached a significant trade agreement, marking the end of months of trade uncertainty [2][4] - The agreement includes a 15% uniform tariff, $600 billion in investments, and $750 billion in energy purchases from the US [4][6] - The deal is seen as a major win for President Trump, who claims it is the largest agreement of its kind [4][7] Trade Agreement Details - The agreement stipulates a 15% tariff on EU products entering the US, with key industries exempted [4][11] - The EU will increase investments in the US by $600 billion and purchase $750 billion worth of US energy products [4][6] - The agreement is expected to benefit the automotive industry and have significant implications for agriculture and the semiconductor sector [4][6] Reactions from EU Officials - EU Commission President von der Leyen stated that the agreement is the best possible outcome given the current circumstances [6] - There are concerns within the EU about the reliance on US liquefied natural gas and the impact of the 15% tariff on the overall EU GDP [12][14] - Some EU officials express dissatisfaction, arguing that the agreement does not align with Europe's fundamental interests and may cause long-term harm [14][15] Market Implications - The agreement alleviates fears of a transatlantic trade war, providing a sense of predictability for financial markets [17][20] - Analysts suggest that the deal is a moderate positive for the stock market, as much of the content may have already been priced in [21] - The removal of the risk of further tariff increases is seen as a significant macroeconomic relief [19][20] Future Considerations - Attention will shift to the interpretation and execution of the agreement, which may present political and technical challenges [23] - The potential for ongoing uncertainty remains, as highlighted by some analysts [22]